Profund Advisors LLC Raises Holdings in Krystal Biotech, Inc. $KRYS

Profund Advisors LLC boosted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 36.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,166 shares of the company’s stock after buying an additional 2,203 shares during the period. Profund Advisors LLC’s holdings in Krystal Biotech were worth $1,122,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in the stock. Brooklyn Investment Group grew its stake in Krystal Biotech by 291.7% in the first quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock valued at $25,000 after purchasing an additional 105 shares during the last quarter. Hantz Financial Services Inc. lifted its position in Krystal Biotech by 8,950.0% during the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after acquiring an additional 179 shares during the last quarter. Twin Tree Management LP purchased a new position in Krystal Biotech in the first quarter worth $29,000. First Horizon Advisors Inc. increased its position in shares of Krystal Biotech by 212.8% during the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after purchasing an additional 166 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company’s stock valued at $58,000 after purchasing an additional 177 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on KRYS shares. Chardan Capital increased their price target on Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Citigroup upped their price target on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Bank of America boosted their price objective on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a report on Friday, October 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Krystal Biotech in a research report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Monday, September 15th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Krystal Biotech presently has a consensus rating of “Moderate Buy” and an average target price of $228.14.

Krystal Biotech Trading Up 1.7%

Shares of KRYS stock opened at $203.00 on Wednesday. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $212.98. The stock has a market cap of $5.89 billion, a P/E ratio of 30.43 and a beta of 0.65. The stock has a 50 day moving average of $176.67 and a 200 day moving average of $154.33.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The firm had revenue of $97.80 million during the quarter, compared to analyst estimates of $93.72 million. On average, research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).